$4.99 Flat Rate Shipping
Any size order is always $4.99
Nuvora was formed in 2007 by a team of experienced drug delivery experts to develop and commercialize oral care products based on the patented SuRe™ (Sustained Release) drug delivery technology.
Dentists and hygienists have always known that optimal oral care is dependent on the length of time ingredients stay active in the mouth. The longer an ingredient is active in the mouth the better it is at fighting bacteria, plaque, bad breath or gum disease. But, conventional oral care products, such as toothpaste or mouthwashes, are only active for a few minutes before they are either expelled or washed away by saliva. As a result, harmful plaque bacteria or bad breath causing bacteria can grow again soon after these products are used. This is where SuRe is different. The sustained release characteristics of the SuRe technology allows for extended delivery of oral care ingredients.
Following months of extensive tests at leading Universities, our researchers developed a small, soft, pliable lozenge that rests comfortably in the mouth where it releases active ingredients, not for seconds or a few minutes, but for hours at a time. This new method of delivering oral care ingredients has shown to be more efficient and effective than conventional technologies.
Nuvora has developed the patented Sustained Release (SuRe®) Technology for making lozenges for release of ingredients into the oral cavity. Conventional oral care systems (paste, rinse, lozenges, etc.) deliver active ingredients for a short period of time, ranging from 30 seconds for rinse products to approximately 2 minutes for paste or 5-10 minutes for lozenges. These short residence times in the mouth are insufficient for adequate treatment of oral problems.
Using the Nuvora technology, 2 products have been developed: Salese for dry mouth, and Dentiva for oral care.
Nuvora has developed the patented Sustained Release (SuRe® Technology) lozenge that can be formulated to last 30 minutes to an hour or longer vs 5 -10 minutes for conventional lozenges, allowing sustained and consistent delivery of active ingredients in the oral cavity. Specifically, this technology is a matrix constructed of a cellulose polymer, essential oils and active ingredients. All base ingredients are registered food products and are GRAS (Generally Recognized As Safe).
The resulting product takes the form of a small, soft lozenge which holds the active ingredients uniformly distributed throughout the lozenge. The dissolution of the lozenge works via a process of slow erosion to delivers an even and continuous stream of active ingredients for the life of lozenge. Thus, a lozenge formulated to last for an hour will continuously release a constant amount of active ingredients for that period of time while maintaining the same pleasant flavor for the entire period.
Efficacy | Sustained release of actives achieves higher bacteria kill rate when compared to the leading anti-bacterial rinse. |
Substantivity | Post treatment SuRe technology maintained higher bacteria kill rate while the rinse treated leg returned to pre treatment levels. |
Dosage | SuRe technology achieved higher bacteria kill rate with a substantially lower dosage of actives:
0.5g SuRe lozenge (essential oils, xylitol) |
Jerry is a serial entrepreneur who brings 40 years of experience in the health care, pharmaceutical and biotech field to Nuvora. He is a co-founder of Nuvora and also oversees the development of new applications for Nuvora’s technology platform. Prior to starting Nuvora, Jerry was co-founder/CEO of Oculex Pharmaceuticals and co-founder/Executive VP of ChemTrak as well as a director at Syva/Syntex Pharmaceuticals and Dow Chemical.
Ben brings 30 years of operations, manufacturing and product development experience to Nuvora. He is co-founder of Nuvora and oversees the company’s product development and manufacturing operations. Before starting Nuvora, Ben was VP of Operations at Oculex Pharmaceuticals. Prior to Oculex, Ben held positions overseeing operations and manufacturing at Monoclonal Antibodies, Biotrack, Abaxis and Syva/Syntex Pharmaceuticals.
Bolko brings 25 years of business management experience in consumer goods and health care fields to Nuvora. Since joining the company, Bolko has overseen all strategic and commercialization efforts for Nuvora’s product line. Prior to joining Nuvora, Bolko was VP of Marketing & Business Strategy at Avicena Group and has held various international senior leadership positions at Gillette and Procter & Gamble.
Dr. Featherstone is a Professor and the Dean at the University of California San Francisco (UCSF) School of Dentistry and is the current Chair of the Department of Preventive and Restorative Dental Sciences.
Dr. Jacobsen is an Adjunct Professor in the Arthur Dugoni School of Dentistry, University of the Pacific and is Vice-Chairman of the ADA Council on Scientific Affairs.
Dr. Mitchell Day served as oral surgeon for the Veterans Affairs Hospital, Palo Alto. He also served as Professor in the Arthur Dugoni School of Dentistry, University of Pacific and as Director of Oral & Maxillofacial Clinics, University of Minnesota.
$4.99 Flat Rate Shipping
Any size order is always $4.99
Got Questions?
BROWSE OUR FAQ
Customer Service
Your satisfaction is our #1 goal